Skip to ContentSkip to Navigation
Research Internal Medicine Experimental Hematology
University Medical Center Groningen

recent publications

Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, Schuringa JJ, Vellenga E. Cell Death Dis. 2017 Jul 13;8(7):e2927. doi: 10.1038/cddis.2017.317.

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia. van der Helm LH, Berger G, Diepstra A, Huls G, Vellenga E. Br J Haematol. 2017 Sep;178(5):810-812

Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches. Hendriks D, Choi G, de Bruyn M, Wiersma VR, Bremer E. Int Rev Cell Mol Biol. 2017;331:289-383. doi: 10.1016/bs.ircmb.2016.10.002

Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Carretta M, de Boer B, Jaques J, Antonelli A, Horton SJ, Yuan H, de Bruijn JD, Groen RWJ, Vellenga E, Schuringa JJ. Exp Hematol. 2017 Jul;51:36-46. doi: 10.1016/j.exphem.2017.04.008. Epub 2017 Apr 26.

Smart niche usage: release its fat and burn it! Schuringa JJ. Blood. 2017 Mar 9;129(10):1239-1240. doi: 10.1182/blood-2017-01-761551. No abstract available.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ. Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells. Hilgendorf S, Folkerts H, Schuringa JJ, Vellenga E. Exp Hematol. 2016 Dec;44(12):1188-1196.e6. doi: 10.1016/j.exphem.2016.08.011. Epub 2016 Sep 8.

Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model. Sontakke P, Carretta M, Jaques J, Brouwers-Vos AZ, Lubbers-Aalders L, Yuan H, de Bruijn JD, Martens AC, Vellenga E, Groen RW, Schuringa JJ. Leukemia. 2016 Oct;30(10):2064-2073. doi: 10.1038/leu.2016.108. Epub 2016 Apr 29.

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. Hendriks D, He Y, Koopmans I, Wiersma VR, van Ginkel RJ, Samplonius DF, Helfrich W, Bremer E. Oncoimmunology. 2016 Jul 6;5(8):e1202390. doi: 10.1080/2162402X.2016.1202390.

Autophagy Proteins ATG5 and ATG7 Are Essential for the Maintenance of Human CD34(+) Hematopoietic Stem-Progenitor Cells. Gomez-Puerto MC, Folkerts H, Wierenga AT, Schepers K, Schuringa JJ, Coffer PJ, Vellenga E. Stem Cells. 2016 Jun;34(6):1651-63. doi: 10.1002/stem.2347. Epub 2016 Mar 28.

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation. Sontakke P, Koczula KM, Jaques J, Wierenga AT, Brouwers-Vos AZ, Pruis M, Günther UL, Vellenga E, Schuringa JJ. PLoS One. 2016 Apr 7;11(4):e0153226. doi: 10.1371/journal.pone.0153226. eCollection 2016.

Clonal evolution in myelodysplastic syndromes. da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH. Nat Commun. 2017 Apr 21;8:15099.

Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions. Capala ME, Pruis M, Vellenga E, Schuringa JJ. Stem Cells Dev. 2016 Mar 1;25(5):427-37. doi: 10.1089/scd.2015.0151. Epub 2016 Feb 8.

Constitutive NF-κB activation in AML: Causes and treatment strategies. Bosman MC, Schuringa JJ, Vellenga E. Crit Rev Oncol Hematol. 2016 Feb;98:35-44. doi: 10.1016/j.critrevonc.2015.10.001. Epub 2015 Oct 18.

The European Hematology Association Roadmap for European Hematology Research: a consensus document. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27.

Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis. van den Boom V, Maat H, Geugien M, Rodríguez López A, Sotoca AM, Jaques J, Brouwers-Vos AZ, Fusetti F, Groen RW, Yuan H, Martens AC, Stunnenberg HG, Vellenga E, Martens JH, Schuringa JJ. Cell Rep. 2016 Jan 12;14(2):332-46. doi: 10.1016/j.celrep.2015.12.034. Epub 2015 Dec 31.

Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models. Sontakke P, Jaques J, Vellenga E, Schuringa JJ . Stem Cells Int. 2016;2016:1625015. doi: 10.1155/2016/1625015. Epub 2016 Aug 25. Review.

Azacitidine in AML: a treatment option? Huls G. Blood. 2015 Jul 16;126(3):283-4. doi: 10.1182/blood-2015-06-648071.

The ever-expanding immunomodulatory role of calreticulin in cancer immunity. de Bruyn M, Wiersma VR, Helfrich W, Eggleton P, Bremer E. Front Oncol. 2015 Feb 20;5:35. doi: 10.3389/fonc.2015.00035

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. Wiersma VR, de Bruyn M, Shi C, Gooden MJ, Wouters MC, Samplonius DF, Hendriks D, Nijman HW, Wei Y, Zhou J, Helfrich W, Bremer E. MAbs. 2015;7(2):321-30. doi: 10.1080/19420862.2015.1007811.

CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. de Bruyn M, Wiersma VR, Wouters MC, Samplonius DF, Klip HG, Helfrich W, Nijman HW, Eggleton P, Bremer E. Oncoimmunology. 2015 Mar 19;4(4):e999536

The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Wiersma VR, de Bruyn M, Wei Y, van Ginkel RJ, Hirashima M, Niki T, Nishi N, Zhou J, Pouwels SD, Samplonius DF, Nijman HW, Eggleton P, Helfrich W, Bremer E. Autophagy. 2015;11(8):1373-88. doi: 10.1080/15548627.2015.1063767.

Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib. van der Helm LH, Bosman MC, Schuringa JJ, Vellenga E. Br J Haematol. 2015 Nov;171(4):652-5. doi: 10.1111/bjh.13418. Epub 2015 Apr 14. No abstract available.

Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2. Capala ME, Maat H, Bonardi F, van den Boom V, Kuipers J, Vellenga E, Giepmans BN, Schuringa JJ. PLoS One. 2015 May 27;10(5):e0128585. doi: 10.1371/journal.pone.0128585. eCollection 2015.

CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia. Korthuis PM, Berger G, Bakker B, Rozenveld-Geugien M, Jaques J, de Haan G, Schuringa JJ, Vellenga E, Schepers H. Leukemia. 2015 Mar;29(3):625-35. doi: 10.1038/leu.2014.259. Epub 2014 Sep 3.

The TAK1-NF-κB axis as therapeutic target for AML. Bosman MC, Schepers H, Jaques J, Brouwers-Vos AZ, Quax WJ, Schuringa JJ, Vellenga E. Blood. 2014 Nov 13;124(20):3130-40. doi: 10.1182/blood-2014-04-569780. Epub 2014 Oct 6.

ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML. Capala ME, Vellenga E, Schuringa JJ. PLoS One. 2014 Oct 31;9(10):e111568. doi: 10.1371/journal.pone.0111568. eCollection 2014.

Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation. Woolthuis CM, Mariani N, Verkaik-Schakel RN, Brouwers-Vos AZ, Schuringa JJ, Vellenga E, de Wolf JT, Huls G. Biol Blood Marrow Transplant. 2014 Jun;20(6):865-71. doi: 10.1016/j.bbmt.2014.03.001. Epub 2014 Mar

Convergence of hypoxia and TGFβ pathways on cell cycle regulation in human hematopoietic stem/progenitor cells. Wierenga AT, Vellenga E, Schuringa JJ. PLoS One. 2014 Mar 31;9(3):e93494. doi: 10.1371/journal.pone.0093494. eCollection 2014.

recent publications

Last modified:21 September 2017 1.38 p.m.